Data from the recent Stop 2G-TKI study confirm that around 60% of patients with chronic myeloid leukaemia who discontinue second-generation BCR-ABL1 tyrosine-kinase inhibitor (TKI) therapy after a sustained deep molecular response remain in remission for longer than 1 year. Importantly, the interim findings suggest that prior response to first-line TKI treatment might predict relapse risk after treatment discontinuation.
Refers to Rea, D. et al. Discontinuation of dasatinib or nilotinib in chronic myeloid leukaemia: interim analysis of the Stop 2G-TKI study. Bloodhttp://dx.doi.org/10.1182/blood-2016–09–742205 (2016)